

Terapie Cellulari per le Malattie Rare – per Tumori Rari

Massimo Dominici

**Full Professor Medical Oncology
Director**

Division of Oncology – Polyclinic of Modena
Laboratory of Cellular Therapy
Department of Medical and Surgical Sciences
University of Modena and Reggio Emilia – Modena


Laboratory of Applied Microscopy and Cell Biology – Mirandola Technopole

- ✓ Rare diseases are defined in the European Union as diseases with a prevalence of fewer than **5 cases out of a population of 10,000**.
- ✓ A **rare tumor** is generally defined as a type of cancer that occurs in a small percentage of the population.
- ✓ While definitions vary, a tumor is often considered rare if it has an incidence of fewer than **6 cases per 100,000 people per year**.




The Relevance of Talking About Rare Cancers: They are Precious!

«Terre Rare»




Major Issues with Rare Cancers

- ✓ Lack of information
- ✓ Misdiagnosis and delay in diagnosis
- ✓ Lack of scientific knowledge
- ✓ Lack of clinical experts
- ✓ Lack of appropriate treatment protocols



PREVALENCE
24% of all people living with cancer in Europe have a rare cancer.



Gastrointestinal & Abdominal

- **Gastrointestinal Stromal Tumor (GIST)** – A rare tumor of the digestive tract.
- **Pancreatic Acinar Cell Carcinoma** – A rare pancreatic cancer type.
- **Pseudomyxoma Peritonei (PMP)** – A rare tumor that produces mucin in the abdomen.

Genitourinary (Kidney, Bladder, Reproductive Organs)

- **Collecting Duct Carcinoma (CDC)** – A rare and aggressive kidney cancer.
- **Small Cell Carcinoma of the Bladder** – A highly rare and aggressive bladder cancer.
- **Ovarian Granulosa Cell Tumor** – A rare ovarian stromal tumor.

Skin & Soft Tissue

- **Merkel Cell Carcinoma** – A rare but aggressive skin cancer.
- **Dermatofibrosarcoma Protuberans (DFSP)** – A slow-growing soft tissue tumor in the skin.

Brain & Nervous System

- **Oligodendroglioma** – A rare brain tumor arising from oligodendrocytes.
- **Ependymoma** – A tumor that develops in the lining of the brain's ventricles or spinal cord.
- **Choroid Plexus Carcinoma** – A rare malignant tumor in the brain, often in children.

Head, Neck & Endocrine

- **Paraganglioma** – A rare neuroendocrine tumor that develops in nerve tissues.
- **Nasopharyngeal Carcinoma** – A rare cancer of the upper part of the throat behind the nose.
- **Anaplastic Thyroid Cancer** – A highly aggressive and rare thyroid malignancy.

Bone & Soft Tissue (Sarcomas)


- **Ewing Sarcoma** – A rare bone or soft tissue cancer, mostly in children and young adults.
- **Chondrosarcoma** – A cartilage-forming bone cancer.
- **Alveolar Soft Part Sarcoma (ASPS)** – A slow-growing but highly metastatic soft tissue tumor.

Treating Patients By Cells

Gene delivery by non-immune cells: To deliver anti-cancer payloads by progenitor cells




Mesenchymal Stromal Cells (MSC)



Lymphocytes (CAR-T)

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Pancreatic Cancers



SCIENTIFIC REPORTS

OPEN Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

Received: 21 August 2017
Accepted: 4 December 2017
Published online: 11 February 2018


Carlotta Sparesi^{1,2}, Giulia Grisvardi^{1,2}, Giulia Golinelli^{1,2}, Filippo Rosignoli^{1,2}, Melina Praper¹, Marco Bestagno¹, Olivia Candini^{1,2}, Tiziana Petrachi¹, Alessandra Racchia¹, Franca Melli¹, Giulia Roveri¹, Giulia Orsi¹, Antonino Maltoni¹, Paola Manzi¹, Elena Veronesi^{1,3}, Maria Serena Piccinini¹, Alice Manghi¹, Massimo Rizzi¹, Edwin M. Horwitz¹, Stefano Cecchi¹, Pierfrancesco Combi¹ & Massimo Dominici^{1,2,4*}


Cell Reports Medicine

CellPress
OPEN ACCESS


Article
Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma

Giulia Grisvardi,^{1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770,771,772,773,774,775,776,777,778,779,780,781,782,783,784,785,786,787,788,789,790,791,792,793,794,795,796,797,798,799,800,801,802,803,804,805,806,807,808,809,810,811,812,813,814,815,816,817,818,819,820,821,822,823,824,825,826,827,828,829,830,831,832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935,936,937,938,939,940,941,942,943,944,945,946,947,948,949,950,951,952,953,954,955,956,957,958,959,960,961,962,963,964,965,966,967,968,969,970,971,972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000}






Lymphocytes (CAR-T)




CAR-T TARGETS

Ewing Sarcoma




Skin & Soft Tissue





Anti-GD2 CAR-T for Ewing's sarcoma (ES)

- ✓ mesenchymal-derived tumor with strong metastatic potential
- ✓ 2nd most common malignant bone tumor in adolescents and young adults
- ✓ disease is higher in males (4.3 cases per million) compared to females (2.6 cases per million).
- ✓ The incidence increases with age, peaking between 10 and 14 years, with 8.2 cases per million in males and 6.6 cases per million in females.
- ✓ About 25% patients with clinical metastatic disease (OS<30%), while 80%-90% have subclinical microscopic widespread disease at baseline



 ES express GD2 and T-cell effectors transduction





Donor 1

Donor 2




CAR-T anti ES in 2D Coculture: TC71



Golinelli G & Chiavelli C et al Submitted


GD2 high



In Vivo Therapeutic Model for a Rare Cancer



Golinelli G & Chiavelli C et al Submitted



H&E


anti-GD2 antibody

anti-GFP antibody


Skin Cancers: Malignant Melanoma



- ✓ As of 2018, the estimated 5-year survival rate is 29.8% in those with stage IV disease at the time of diagnosis (United States)
- ✓ Noncutaneous forms of melanoma, including mucosal and ocular subtypes, classically portend an even worse prognosis
- ✓ In 2022, it is estimated that there will be more than 106.000 new cases of invasive melanoma with 7.180 melanoma-related deaths in the United States
- ✓ According to GLOBOCAN for 2020, there were 324,635 cases of melanoma worldwide, representing 1.7% of all cancers and 57,043 melanoma deaths or 0.6% of cancer-related mortality
- ✓ 15000 new cases/yr in Italy




Allogeneic anti-GD2 CAR T against SK-MEL-5 Melanoma Cells in 3D



Chiavelli, Pugliese in preparation

Melanoma Metastatic Lymph Node Samples: Primary Tumor Cell Isolation


PATIENT ID	MEL CM64	MEL BF54	MEL TG65
GENDER AGE	M 59	F 69	M 57
DIAGNOSIS	Melanoma	Melanoma	Melanoma
DISSOCIATION DATE	16.09.2022	23.11.2022	03.04.2023
STARTING MATERIAL	Metastatic axillary lymph node right	Metastatic obturator-iliac lymph node right	Metastatic axillary lymph node right
IHC MARKERS	MelanA, S100, PDL1	HMB45, S100mono, Melcocktail	S100mono
MOLECULAR MARKERS	BRAF p.V600K	BRAF p.V600K	BRAF p.V600E
DISSOCIATION PROTOCOL	Medium, Tough	Medium	Tough
CELL MEDIA	RPMI + 10% FBS, RPMI + HMGS2, DMEM-F12 + 10% FBS, DMEM-F12 + HMGS2	254 + HMGS2, RPMI + HMGS2, DMEM-F12 + 10% FBS	254 + HMGS2, DMEM-F12 + 10% FBS
CELL YIELD	High	High	Low




Chiavelli, Pugliese in preparation

Patient-derived Melanoma Cells Characterization


PATIENT ID	MEL BF54
GENDER AGE	F 69
DIA<<<<<GNOSIS	Melanoma
DISSOCIATION DATE	23.11.2022
STARTING MATERIAL	Metastatic obturator-iliac lymph node right
IHC MARKERS	HMB45, S100mono, Melcocktail
MOLECULAR MARKERS	BRAF p.V600K




Chiavelli, Pugliese in preparation



GD2⁺ cells 92.0%




MelCock⁺ cells 98.5%





CSPG4⁺ cells 99.2%



Autologous **GFP Only T-cells** against Patient-derived Melanoma



Autologous **anti-GD2 CAR T** against Patient-derived Melanoma



The Relevance of Investigating Rare Cancers

- ✓ **Unmet Medical Needs** – Rare cancers often have limited treatment options and lower survival rates due to less research and fewer clinical trials. Understanding them can lead to better therapies.
- ✓ **Scientific Discovery** – Studying rare cancers can reveal unique genetic mutations and biological mechanisms that may apply to more common cancers, leading to broader medical advancements.
- ✓ **Precision Medicine** – Research on rare cancers can contribute to personalized treatments, as many rare cancers are driven by specific genetic mutations that can be targeted with precision therapies.
- ✓ **Equity in Healthcare** – Patients with rare cancers deserve the same attention and advancements as those with more common cancers. Improving research ensures they have access to better diagnostics and treatments.
- ✓ **Potential Links to Other Diseases** – Rare cancers may share pathways with more common diseases, providing insights into broader medical conditions, including inflammation, immune system function, and genetic disorders.





Finanziato dall'Unione europea
NextGenerationEU



Ministero dell'Università e della Ricerca



Italiadomani
PIANO NAZIONALE DI RIPRESA E RESILIENZA

UNIMORE
UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA



Laboratory of Cellular Therapies

Dr. Giulia Grisendi
Dr. Aurora Melandri
Dr. Valentina Masciale
Dr. Mohein Farshchian
Dr. Fabio Lepore

Dr. Giulia Golinelli
Dr. Chiara Chiavelli
Dr. Marco Silingardi
Dr. Giuseppe Pugliese
Dr. Giulia Rovesti
Dr. Lucia Trudu
Dr. Leonardo Brini

Dr. Ilenia Mastrolia
Dr. Virginia Catani
Dr. Marta Calabria




SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero-Universitaria di Modena



UNIMORE
UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA

GRAZIE!



massimo.dominici@unimore.it

Molecular pathology
Plastic surgery
Thoracic Surgery
Pulmonology
Pathology
Pediatrics
Neurosurgery
Transplant surgery
Radiology

Cossarizza Lab
Biagini Lab
Vandelli/Tosi Lab
Tagliafico Lab
Recchia Lab
Giuliani Lab
Zappavigna Lab
Carnevale Lab

Andrea Spallazani
Annalisa Fontana
Elisa Pettorelli

Pierfranco Conte

